
Sign up to save your podcasts
Or


The company that developed Cologuard also developed this “next generation” multitarget stool DNA test, and has applied for U.S. FDA approval. The new test appears to have similar sensitivity and higher specificity than its predecessor — which means fewer false positives.
https://www.nejm.org/doi/10.1056/NEJMoa2310336
By Questioning Medicine4.9
7474 ratings
The company that developed Cologuard also developed this “next generation” multitarget stool DNA test, and has applied for U.S. FDA approval. The new test appears to have similar sensitivity and higher specificity than its predecessor — which means fewer false positives.
https://www.nejm.org/doi/10.1056/NEJMoa2310336

7,599 Listeners

14,818 Listeners

135 Listeners

700 Listeners

496 Listeners

263 Listeners

2,443 Listeners

3,340 Listeners

56,517 Listeners

1,150 Listeners

28,406 Listeners

6,398 Listeners

373 Listeners

29,164 Listeners

1,304 Listeners